PRESS RELEASES

2019

June 4, 2019 - VBL Therapeutics to Provide Additional Details on the New VB-111 Data Presented Earlier This Week at ASCO, in a Presentation at the 2019 BIO International Convention Today View this release →
June 3, 2019 - Radiographic Analysis of VB-111 Phase 2 and 3 Clinical Trials in Recurrent Glioblastoma Shows Survival Benefit Associated with Objective Responses and Distinct Signature of VB-111 Activity
June 3, 2019 - VBL Final Phase 1/2 Study Results Presented at ASCO Demonstrate VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer
May 23, 2019 - VBL Therapeutics Announces Presentations at the 2019 ASCO Annual Meeting and the BIO International Convention
May 15, 2019 - VBL Therapeutics Announces First Quarter 2019 Financial Results
May 6, 2019 - VBL Therapeutics to Report First Quarter 2019 Financial Results on May 15
March 28, 2019 - VBL Therapeutics Announces Year Ended December 31, 2018 Financial Results and Provides Corporate Update
March 25, 2019 - VBL Therapeutics to Present at Upcoming Conferences in April
March 19, 2019 - VBL Presents New Data on Potential of VB-111 to Stimulate the Immune System and Drive Immune Cells to Infiltrate Tumor Microenvironment
March 14, 2019 - VBL Therapeutics to Report Fiscal Year 2018 Financial Results on March 28
March 11, 2019 - VBL Therapeutics to Present at the Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women’s Cancer on March 18
February 26, 2019 - VBL Presents New Data on the Potential of its Novel VB-600 Platform for Nonalcoholic Steatohepatitis (NASH) and Rheumatoid Arthritis (RA)
February 20, 2019 - VBL Therapeutics Awarded $2.9 Million Non-Dilutive Grant by the Israel Innovation Authority
February 19, 2019 - VBL Therapeutics to Present Data on its Novel VB-600 Platform at Keystone Conference on February 26